Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).

Br J Cancer · 2018 · PMC5846072 · PMID 29438373

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

Anlotinib therapy had a prolonged OS of 3 months, but failed to reach statistical significance (HR=0.78; 95%CI, 0.51–1.18).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.